This trial will compare two cancer treatments to see which is more effective in treating breast cancer that is Advanced or has Metastasized and is estrogen receptor and human epidermal growth factor receptor 2 positive.
2 Primary · 23 Secondary · Reporting Duration: From randomization until death from any cause (up to 42 months)
Active Control
Experimental Treatment
320 Total Participants · 2 Treatment Groups
Primary Treatment: Giredestrant · No Placebo Group · Phase 3
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: